Andrew Guggenhime
Direttore Finanziario/CFO presso VAXCYTE, INC.
Patrimonio netto: 7 M $ in data 31/05/2023
Relazioni attive
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| Grant Pickering | M | 56 | 11 anni | |
| Rachel Haurwitz | M | 37 | 13 anni | |
| Mikhail Eydelman | M | 43 | 2 anni | |
| John McLaughlin | M | 72 | 16 anni | |
| Halley Gilbert | F | 54 | 5 anni | |
| Janet Graesser | F | - | 3 anni | |
| Teri Loxam | F | 52 | 3 anni | |
| Heather Wasserman | M | - | 4 anni | |
| Ran Zheng | F | 61 | 3 anni | |
| Jason O’Byrne | M | 55 | 3 anni | |
| Natalie Sacks | M | 59 | 6 anni | |
| Dara Richardson-Heron | M | 60 | 3 anni | |
| David Johnson | M | 55 | 2 anni | |
| Jacks Lee | M | 60 | 1 anni | |
| Carlos Paya | M | 65 | 3 anni | |
| Jeff Fairman | M | 60 | 11 anni | |
| K. Hirth | M | 72 | 8 anni | |
| Heath Lukatch | M | 56 | 6 anni | |
| Scott Braunstein | M | 60 | 3 anni | |
| Barbara McClung | F | 69 | 9 anni | |
| Anne Drapeau | F | 57 | 3 anni | |
| Nancy Whiting | M | 51 | 3 anni | |
| Jakub Simon | M | - | 2 anni | |
| Cindy Hayashi | F | - | 8 anni | |
| Ryan Fischesser | M | - | - | |
| Reigin Zawadzki | F | - | 1 anni | |
| Elaine Alambra | F | - | - | |
| Elvia Cowan | F | 51 | 2 anni | |
| Mark Wiggins | M | 68 | 2 anni | |
| Carly Loeb | M | - | 6 anni | |
| Gary Thompson | M | - | 6 anni | |
| James Wassil | M | 54 | 5 anni | |
| Whitney Jones | F | - | - | |
| Gordon Brooks | M | - | 4 anni | |
| Harpreet Dhaliwal | M | - | 3 anni | |
| Steven Kanner | M | 65 | 7 anni | |
| Philip Johnson | M | 59 | 4 anni | |
| Paul Sauer | M | 63 | 8 anni | |
| Ruhi Khan | F | 49 | 3 anni | |
| Timothy Kelly | M | 55 | - | |
| H. Hogan | M | 61 | 1 anni |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| Michael York | M | 59 | 2 anni | |
| Faheem Hasnain | M | 65 |
Abbott Biotherapeutics Corp.
 Abbott Biotherapeutics Corp. Pharmaceuticals: MajorHealth Technology Abbott Biotherapeutics Corp. engages in the identification and development of oncology therapeutics. The firm's products in development include Daclizumab, a monoclonal antibody in Phase IIb clinical studies that binds to the alpha chain of the interleukin-2 receptor on activated T cells; and Volociximab, a chimeric monoclonal antibody in Phase I clinical studies that inhibits the functional activity of a protein in activated endothelial cells. The company was founded in 2008 and is headquartered in Redwood City, CA. | 2 anni |
| Herbert Cross | M | 52 |
Abbott Biotherapeutics Corp.
Abbott Biotherapeutics Corp. Pharmaceuticals: MajorHealth Technology Abbott Biotherapeutics Corp. engages in the identification and development of oncology therapeutics. The firm's products in development include Daclizumab, a monoclonal antibody in Phase IIb clinical studies that binds to the alpha chain of the interleukin-2 receptor on activated T cells; and Volociximab, a chimeric monoclonal antibody in Phase I clinical studies that inhibits the functional activity of a protein in activated endothelial cells. The company was founded in 2008 and is headquartered in Redwood City, CA.
Neoforma, Inc.
 Neoforma, Inc. Medical DistributorsDistribution Services Neoforma, Inc. provides e-commerce services to healthcare industry. It also provides supply chain management solutions between hospitals and suppliers. The Company was founded in 1996 and is located in SanJose, CA. | 6 anni |
| Mark McDade | M | 69 | 12 anni | |
| Carol Gallagher | M | 59 |
Calistoga Pharmaceuticals, Inc.
 Calistoga Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Calistoga Pharmaceuticals, Inc. develops and manufactures pharmaceutical products. The company was founded by Michael W. Gallatin, Roger Ulrich and Neil Giese in March 2006 and is headquartered in Tumwater, WA. | 7 anni |
| Francis Sarena | M | 53 |
Abbott Biotherapeutics Corp.
Abbott Biotherapeutics Corp. Pharmaceuticals: MajorHealth Technology Abbott Biotherapeutics Corp. engages in the identification and development of oncology therapeutics. The firm's products in development include Daclizumab, a monoclonal antibody in Phase IIb clinical studies that binds to the alpha chain of the interleukin-2 receptor on activated T cells; and Volociximab, a chimeric monoclonal antibody in Phase I clinical studies that inhibits the functional activity of a protein in activated endothelial cells. The company was founded in 2008 and is headquartered in Redwood City, CA. | 4 anni |
| Kurt von Emster | M | 56 |
Abbott Biotherapeutics Corp.
Abbott Biotherapeutics Corp. Pharmaceuticals: MajorHealth Technology Abbott Biotherapeutics Corp. engages in the identification and development of oncology therapeutics. The firm's products in development include Daclizumab, a monoclonal antibody in Phase IIb clinical studies that binds to the alpha chain of the interleukin-2 receptor on activated T cells; and Volociximab, a chimeric monoclonal antibody in Phase I clinical studies that inhibits the functional activity of a protein in activated endothelial cells. The company was founded in 2008 and is headquartered in Redwood City, CA. | 9 anni |
| Eugene Bauer | M | 81 | 10 anni | |
| Richard Heyman | M | 66 | 9 anni | |
| Preston Klassen | M | 55 | 3 anni | |
| Kenneth Song | M | 49 | 4 anni | |
| Moncef Slaoui | M | 64 | 4 anni | |
| Bradford Goodwin | M | 69 |
Abbott Biotherapeutics Corp.
Abbott Biotherapeutics Corp. Pharmaceuticals: MajorHealth Technology Abbott Biotherapeutics Corp. engages in the identification and development of oncology therapeutics. The firm's products in development include Daclizumab, a monoclonal antibody in Phase IIb clinical studies that binds to the alpha chain of the interleukin-2 receptor on activated T cells; and Volociximab, a chimeric monoclonal antibody in Phase I clinical studies that inhibits the functional activity of a protein in activated endothelial cells. The company was founded in 2008 and is headquartered in Redwood City, CA. | 4 anni |
| Thomas Wiggans | M | 72 | 10 anni | |
| Leonard Patrick Gage | M | 81 | 5 anni | |
| Jane Wright-Mitchell | F | 55 | 2 anni | |
| Daljit Singh Aurora | M | 55 | 5 anni | |
| Khush F. Mehta | M | - | - | |
| Ronald M. Evans | M | 74 | 9 anni | |
| Robert Hopfner | M | 51 | 4 anni | |
| Catherine C. Lee | F | 50 | 2 anni | |
| Steve Kunszabo | M | - | - | |
| Ami Knoefler | F | - |
Abbott Biotherapeutics Corp.
Abbott Biotherapeutics Corp. Pharmaceuticals: MajorHealth Technology Abbott Biotherapeutics Corp. engages in the identification and development of oncology therapeutics. The firm's products in development include Daclizumab, a monoclonal antibody in Phase IIb clinical studies that binds to the alpha chain of the interleukin-2 receptor on activated T cells; and Volociximab, a chimeric monoclonal antibody in Phase I clinical studies that inhibits the functional activity of a protein in activated endothelial cells. The company was founded in 2008 and is headquartered in Redwood City, CA. | 4 anni |
| Robert Zollars | M | 66 |
Neoforma, Inc.
Neoforma, Inc. Medical DistributorsDistribution Services Neoforma, Inc. provides e-commerce services to healthcare industry. It also provides supply chain management solutions between hospitals and suppliers. The Company was founded in 1996 and is located in SanJose, CA. | 7 anni |
| Luis Peña | M | 61 | 10 anni | |
| Valerie Barnett | F | 49 | 5 anni | |
| Jeffrey Jonker | M | 51 | 2 anni | |
| Lisa Lee | F | - |
Merrill Lynch & Co., Inc.
| 9 anni |
| John McHutchison | M | 66 | 3 anni | |
| Julia C. Owens | M | 51 | 2 anni | |
| Kathleen Sebelius | F | 75 | 5 anni | |
| Ajit Singh | M | 60 | - | |
| Kristina Burow | F | 50 | 7 anni | |
| Mark McCamish | M | 72 |
Abbott Biotherapeutics Corp.
Abbott Biotherapeutics Corp. Pharmaceuticals: MajorHealth Technology Abbott Biotherapeutics Corp. engages in the identification and development of oncology therapeutics. The firm's products in development include Daclizumab, a monoclonal antibody in Phase IIb clinical studies that binds to the alpha chain of the interleukin-2 receptor on activated T cells; and Volociximab, a chimeric monoclonal antibody in Phase I clinical studies that inhibits the functional activity of a protein in activated endothelial cells. The company was founded in 2008 and is headquartered in Redwood City, CA. | 2 anni |
| Cynthia Shumate | F | 62 | 4 anni | |
| Richard Murray | M | 65 | 5 anni | |
| Patricia Millican | F | 51 | 7 anni | |
| Michael Kamarck | M | 73 | 2 anni | |
| Jon Saxe | M | 88 | 19 anni | |
| Gary Lyons | M | 73 |
Abbott Biotherapeutics Corp.
Abbott Biotherapeutics Corp. Pharmaceuticals: MajorHealth Technology Abbott Biotherapeutics Corp. engages in the identification and development of oncology therapeutics. The firm's products in development include Daclizumab, a monoclonal antibody in Phase IIb clinical studies that binds to the alpha chain of the interleukin-2 receptor on activated T cells; and Volociximab, a chimeric monoclonal antibody in Phase I clinical studies that inhibits the functional activity of a protein in activated endothelial cells. The company was founded in 2008 and is headquartered in Redwood City, CA. | 2 anni |
| Paul W. Sandman | M | 76 | 12 anni | |
| Dan Eckert | M | 59 |
Neoforma, Inc.
Neoforma, Inc. Medical DistributorsDistribution Services Neoforma, Inc. provides e-commerce services to healthcare industry. It also provides supply chain management solutions between hospitals and suppliers. The Company was founded in 1996 and is located in SanJose, CA. | 7 anni |
| William Ringo | M | 78 | 6 anni | |
| Robert J. Adelman | M | 61 | 6 anni | |
| Becky Chaitesipaseut | F | - | - | |
| Jake Nunn | M | 53 | 9 anni | |
| William Newell | M | 66 | 8 anni | |
| Jaisim Shah | M | 63 |
Abbott Biotherapeutics Corp.
Abbott Biotherapeutics Corp. Pharmaceuticals: MajorHealth Technology Abbott Biotherapeutics Corp. engages in the identification and development of oncology therapeutics. The firm's products in development include Daclizumab, a monoclonal antibody in Phase IIb clinical studies that binds to the alpha chain of the interleukin-2 receptor on activated T cells; and Volociximab, a chimeric monoclonal antibody in Phase I clinical studies that inhibits the functional activity of a protein in activated endothelial cells. The company was founded in 2008 and is headquartered in Redwood City, CA. | 9 anni |
| Amir Nashat | M | 51 | 8 anni | |
| Jeffrey Long-McGie | M | 48 | - | |
| Patrick Heron | M | 53 | 4 anni | |
| David Cohen | M | 59 | 6 anni | |
| Wende Hutton | F | 63 | 4 anni | |
| Matthew Fust | M | 59 | 6 anni | |
| Ademola B. Odunsi | M | - |
Merrill Lynch & Co., Inc.
| 6 anni |
| Janet Johnston | F | - |
Merrill Lynch & Co., Inc.
| 4 anni |
| Harry Mcmahon | M | 70 |
Merrill Lynch & Co., Inc.
| 10 anni |
| Michael Gordon | M | 54 |
Merrill Lynch & Co., Inc.
| 13 anni |
Statistiche
| Paese | Relazioni | % del totale |
|---|---|---|
| Stati Uniti | 99 | 100.00% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Andrew Guggenhime
- Contatti personali
